Abstract
Background: Tuberculosis (TB) is one of the most important causes of mortality due to infectious diseases. The development of a vaccine inducing superior protection than BCG is a top priority for the future control of the disease.
Methods: We reviewed the literature related with the impact of the host, microbiome and environmental elements in response to vaccination, with special emphasis on TB.
Results: This review introduces the term “Self-Antigenic Universe” (SAU) which consists of “Host” & “Guests” (classical microbiota and other organisms with relatively stable presence in the host) and “Familiar Visitors”: (organisms and substances which are often present in the host). We provide multiple examples of how SAU influences the immune response to Mycobacterium tuberculosis and its impact on TB vaccine development.
Conclusion: The immune response induced by antigens/epitopes present in SAU could have carrier effect and elicit specific effector and/or regulatory immune responses potentially useful for the development of new vaccines. This aspect should be considered for the development of tailored vaccines with superior efficacy for the prevention of TB.
Keywords: Mycobacterium tuberculosis, microbiota, vaccine, host, tuberculosis, self, immune response.
Current Pharmacogenomics and Personalized Medicine
Title:“Self-Antigenic Universe” and Tuberculosis Vaccine Development
Volume: 13 Issue: 1
Author(s): Maria E. Sarmiento, Armando Acosta and Mohd Nor Norazmi
Affiliation:
Keywords: Mycobacterium tuberculosis, microbiota, vaccine, host, tuberculosis, self, immune response.
Abstract: Background: Tuberculosis (TB) is one of the most important causes of mortality due to infectious diseases. The development of a vaccine inducing superior protection than BCG is a top priority for the future control of the disease.
Methods: We reviewed the literature related with the impact of the host, microbiome and environmental elements in response to vaccination, with special emphasis on TB.
Results: This review introduces the term “Self-Antigenic Universe” (SAU) which consists of “Host” & “Guests” (classical microbiota and other organisms with relatively stable presence in the host) and “Familiar Visitors”: (organisms and substances which are often present in the host). We provide multiple examples of how SAU influences the immune response to Mycobacterium tuberculosis and its impact on TB vaccine development.
Conclusion: The immune response induced by antigens/epitopes present in SAU could have carrier effect and elicit specific effector and/or regulatory immune responses potentially useful for the development of new vaccines. This aspect should be considered for the development of tailored vaccines with superior efficacy for the prevention of TB.
Export Options
About this article
Cite this article as:
Sarmiento E. Maria, Acosta Armando and Norazmi Nor Mohd, “Self-Antigenic Universe” and Tuberculosis Vaccine Development, Current Pharmacogenomics and Personalized Medicine 2015; 13 (1) . https://dx.doi.org/10.2174/187569211301151228153558
DOI https://dx.doi.org/10.2174/187569211301151228153558 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Recent Advances in Pegylated Interferon Antiviral Therapy of Chronic Hepatitis C
Anti-Infective Agents in Medicinal Chemistry Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma
Current Vascular Pharmacology Matrix Systems for siRNA Delivery
Current Topics in Medicinal Chemistry Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry Gene Therapy for Gastric Diseases
Current Gene Therapy Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-squamous Tumors of the Oropharynx and Oral Cavity: CT and MR Imaging Findings with Clinical- Pathologic Correlation
Current Medical Imaging Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry The Role of Stress Proteins in Prostate Cancer
Current Genomics Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design